{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-060093","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.251085+00:00","generated_at":"2026-05-31T22:40:32.140834+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"60 Degrees Pharma enrolls first patient in tafenoquine babesiosis study at Tufts Medical Center","bullets":["IRB approval received for open-label expanded access study of tafenoquine in immunocompromised patients with persistent babesiosis.","Goal is to confirm 80% cure rate (30-100% CI) from Yale April 2024 case series published in Clinical Infectious Diseases.","Three-part program: acute hospitalized (enrolling), expanded access (announced), and chronic babesiosis (planned, gated by NC State study).","Company plans to file NDA for supplemental babesiosis indication by Q2 2026.","U.S. accessible market estimate: 38,000 acute immunosuppressed patients and at least 375,000 chronic babesiosis patients through 2035."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-060093","json":"https://secwatch.observer/filing/0001213900-24-060093.json","markdown":"https://secwatch.observer/filing/0001213900-24-060093.md","text":"https://secwatch.observer/filing/0001213900-24-060093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024060093/0001213900-24-060093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024060093/ea0209161-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:40:32.140834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}